Dare Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $10.51M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $200.00K | $-0.20 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $152.46K | $-0.20 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $2.26K | $-0.28 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | -$21.17K | $-0.45 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $41.69K | $-0.55 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Dare Bioscience filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Announces Pricing of $6.0 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Interim Phase 3 Results Highlight Potential of Ovaprene ® , Novel Hormone-Free Contraceptive
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bioscience Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Bioscience Announces Executive Team and Board of Directors Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Secures $12 million in Royalty-backed Investment Structure $5 million at closing and up to $7 million of additional committed
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K